RUNX1 and ovarian cancer: In cohorts of glioma, pancreatic cancer, colorectal cancer, cervical cancer, renal cancer, lung cancer, ovarian cancer, and gastric cancer, RUNX1 is a worse predictive indicator (Lin 2022).